FDA approves Amgen’s BLINCYTO for acute lymphoblastic leukaemia

17 Jun 2024
www.pharmaceutical-technology.com
Phase 3Drug ApprovalClinical ResultImmunotherapyBreakthrough Therapy
FDA approves Amgen’s BLINCYTO for acute lymphoblastic leukaemia
Preview
Source: Pharmaceutical Technology
In a Phase III trial, Amgen’s BLINCYTO plus consolidation chemotherapy significantly improved overall survival versus chemotherapy alone. Credit: JHVEPhoto / Shutterstock.
The US Food and Drug Administration (FDA) has approved Amgen’s BLINCYTO (blinatumomab) for CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukaemia (B-ALL)CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukaemia (B-ALL) patients in the consolidation phase.
This new indication for BLINCYTO is for adults and paediatric patients aged over one month with B-ALL, irrespective of the measurable residual disease status.
The approval is based on the Phase III E1910 clinical trial, led by ECOG-ACRIN Cancer Research GroupCancer Research Group, which evaluated BLINCYTO in the postinduction consolidation treatment phase of newly diagnosed patients.
The study aimed to deepen remission and achieve long-term responses.
Trial data showed that adding BLINCYTO to consolidation chemotherapy significantly improved overall survival (OS) compared to chemotherapy alone.
See Also:Monlunabant by Inversago Pharma for Obesity: Likelihood of Approval
FDA approves Amgen’s BLINCYTO for acute lymphoblastic leukaemia
Preview
Source: Pharmaceutical Technology
Monlunabant by Inversago Pharma for Metabolic Syndrome: Likelihood of Approval
FDA approves Amgen’s BLINCYTO for acute lymphoblastic leukaemia
Preview
Source: Pharmaceutical Technology
The three-year OS rate was 84.8% for patients receiving BLINCYTO plus chemotherapy, versus 69% for those on chemotherapy alone.
After four and a half years of median follow-up, the five-year OS was 82.4% in the BLINCYTO and chemotherapy arm versus 62.5% in the chemotherapy group.
Amgen research and development executive vice-president and chief scientific officer Jay Bradner stated: “B-ALL is an aggressive blood cancer with enduring high unmet need. BLINCYTO has helped thousands of patients with B-ALL over the last 10 years.
“The approval in the frontline consolidation phase, regardless of MRD status, allows us to reach more patients than ever with this transformative first-in-class bispecific T-cell engager (BiTE) therapy.”
BLINCYTO, a (BiTE) immuno-oncology therapy targeting CD19 surface antigens on B cells, has obtained breakthrough therapy and priority review designations from the FDA.
It is already approved in the US for multiple indications such as CD19-positive B-ALLCD19-positive B-ALL in first or second complete remission with MRD ≥0.1%, and relapsed or refractory CD19-positive B-ALL in adults and paediatric patients aged above one month.
In May 2024, Amgen‘s Bkemv (eculizumab-aeeb) received FDA approval for use as the first interchangeable biosimilar to Soliris (eculizumab) for the treatment of specific rare diseases.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.